Anti-Inflammatory Effects of Idebenone Attenuate LPS-Induced Systemic Inflammatory Diseases by Suppressing NF-κB Activation
Open Access
- 25 January 2024
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 13 (2) , 151
Abstract
Inflammation is a natural protective process through which the immune system responds to injury, infection, or irritation. However, hyperinflammation or long-term inflammatory responses can cause various inflammatory diseases. Although idebenone was initially developed for the treatment of cognitive impairment and dementia, it is currently used to treat various diseases. However, its anti-inflammatory effects and regulatory functions in inflammatory diseases are yet to be elucidated. Therefore, this study aimed to investigate the anti-inflammatory effects of idebenone in cecal ligation puncture-induced sepsis and lipopolysaccharide-induced systemic inflammation. Murine models of cecal ligation puncture-induced sepsis and lipopolysaccharide-induced systemic inflammation were generated, followed by treatment with various concentrations of idebenone. Additionally, lipopolysaccharide-stimulated macrophages were treated with idebenone to elucidate its anti-inflammatory effects at the cellular level. Idebenone treatment significantly improved survival rate, protected against tissue damage, and decreased the expression of inflammatory enzymes and cytokines in mice models of sepsis and systemic inflammation. Additionally, idebenone treatment suppressed inflammatory responses in macrophages, inhibited the NF-κB signaling pathway, reduced reactive oxygen species and lipid peroxidation, and normalized the activities of antioxidant enzyme. Idebenone possesses potential therapeutic application as a novel anti-inflammatory agent in systemic inflammatory diseases and sepsis.Keywords
All Related Versions
Funding Information
- Ministry of Education (NRF-2021R1A2C1094382, NRF-2022R1A2C1091865, 2E33060-24-P011, KGM5322422)
- KIST Institutional Program (NRF-2021R1A2C1094382, NRF-2022R1A2C1091865, 2E33060-24-P011, KGM5322422)
- KRIBB Research Initiative Program (NRF-2021R1A2C1094382, NRF-2022R1A2C1091865, 2E33060-24-P011, KGM5322422)
This publication has 35 references indexed in Scilit:
- ROS Function in Redox Signaling and Oxidative StressCurrent Biology, 2014
- Reactive Oxygen Species in Inflammation and Tissue InjuryAntioxidants & Redox Signaling, 2014
- Coenzyme Q10 Ameliorates Pain and Cartilage Degradation in a Rat Model of Osteoarthritis by Regulating Nitric Oxide and Inflammatory CytokinesPLOS ONE, 2013
- Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse Model of Leber’s Hereditary Optic NeuropathyPLOS ONE, 2012
- Crosstalk of reactive oxygen species and NF-κB signalingCell Research, 2010
- The Highly Expressed and Inducible Endogenous NAD(P)H:quinone Oxidoreductase 1 in Cardiovascular Cells Acts as a Potential Superoxide ScavengerCardiovascular Toxicology, 2007
- Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulationsMitochondrion, 2007
- Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenoneJournal of Cosmetic Dermatology, 2005
- Quinone analogues regulate mitochondrial substrate competitive oxidationBiochemical and Biophysical Research Communications, 2004
- Idebenone in senile dementia of Alzheimer type: A multicentre studyArchives of Gerontology and Geriatrics, 1992